F031 Side Effects May Include: Illustrative Cases of Dermatologic Adverse Events
DESCRIPTION
Dermatologists are frequently called upon to diagnose and manage patients with suspected drug rashes. With the pace of new medication development, it is important but difficult to keep up with the spectrum of side effects relevant to dermatology. This case-based interactive session will explore dermatologic adverse events. This will include cutaneous adverse reactions of non-dermatologic medications, as well as rare potential side effects of medications commonly prescribed by dermatologists. Cases will be selected that illustrate the clinical presentation, differential diagnosis, workup, and management of a variety of cutaneous adverse reactions and dermatologic drug side effects in different patient subtypes.
LEARNING OBJECTIVES
Recognize different forms of cutaneous adverse reactions and uncommon side effects of dermatologic medications.
Manage patients with dermatologic adverse reactions and develop evaluation and treatment plans based on reaction type.
Determine the most likely causative medications for specific cutaneous adverse reactions.
DIRECTOR
Margaret (Molly) Moye, MD, FAAD
SPEAKERS
Daniel Charles Butler, MD, FAAD
Jae Jung, MD, PhD, FAAD
Caroline Nelson, MD, FAAD
Robert J. Smith, MD, FAAD
DISCLOSURES
Daniel Charles Butler, MD, FAAD
AbbVie – Investigator(Grants/Research Funding); Galderma – Advisory Board(Fees); Leo Pharma Inc – Advisory Board(Fees); Novartis – Advisory Board(Honoraria); Pfizer Inc. – Investigator(Grants/Research Funding); Regeneron – Speaker(Honoraria);
Jae Jung, MD, PhD, FAAD
Adgero Biopharmaceuticals Holdings, Inc. – Consultant(Honoraria); Amgen – Consultant(Honoraria); Merck & Co., Inc – Investigator(Grants/Research Funding); Regeneron – Investigator(Grants/Research Funding);
Margaret (Molly) Moye, MD, FAAD
Forefront Dermatology – Advisory Board(Stock Options), Employee (w-2 relationship)(Salary), Stockholder(Stock);
Caroline Nelson, MD, FAAD
Boehringer Ingelheim – Advisory Board(Honoraria), Investigator(Grants/Research Funding);
Robert J. Smith, MD, FAAD
No financial relationships exist with ineligible companies.